Stocks · News reference
IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
IGC Pharma Announces Completion Of 168-Patient Enrollment In Phase 2 Trial Of IGC-AD1 For Alzheimer's Agitation; Topline Data Expected Q4 2026
'Federal Court Rejects Marijuana Opponents’ Request To Block Trump’s Rescheduling Move' - Marijuana Moment
https://www.marijuanamoment.net/federal-court-rejects-marijuana-opponents-request-to-block-trumps-rescheduling-move/
President And Founder Of Seabreeze Capital Partners LP Dougie Kass Posts On X "We have moved to super size $MSOS and individual cannabis stocks in the belief that a favorable rescheduling announcement will come shortly."
https://x.com/DougKass/status/2093394146182480247